BioCryst Pharmaceuticals,Inc. (BCRX)

[0210]

FDA's approval: overwhelmingly positive results, late-stage study of Orladeyo.

"There are other FDA-approved HAE drugs on the market. However, Anthony Castaldo, CEO of the U.S. Hereditary Angioedema Association, noted that Orladeyo is "the first orally administered non-steroidal option for preventing HAE attacks." He added that the approval of the drug "represents an important and welcome step in making more treatment options available to physicians and patients."